Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;21(12):987-994.
doi: 10.1111/nep.12864.

Lanthanum Carbonate: Safety Data After 10 Years

Free PMC article

Lanthanum Carbonate: Safety Data After 10 Years

Alastair J Hutchison et al. Nephrology (Carlton). .
Free PMC article


Despite 10 years of post-marketing safety monitoring of the phosphate binder lanthanum carbonate, concerns about aluminium-like accumulation and toxicity persist. Here, we present a concise overview of the safety profile of lanthanum carbonate and interim results from a 5-year observational database study (SPD405-404; identifier: NCT00567723). The pharmacokinetic paradigms of lanthanum and aluminium are different in that lanthanum is minimally absorbed and eliminated via the hepatobiliary pathway, whereas aluminium shows appreciable absorption and is eliminated by the kidneys. Randomised prospective studies of paired bone biopsies revealed no evidence of accumulation or toxicity in patients treated with lanthanum carbonate. Patients treated with lanthanum carbonate for up to 6 years showed no clinically relevant changes in liver enzyme or bilirubin levels. Lanthanum does not cross the intact blood-brain barrier. The most common adverse effects are mild/moderate nausea, diarrhoea and flatulence. An interim Kaplan-Meier analysis of SPD405-404 data from the United States Renal Data System revealed that the median 5-year survival was 51.6 months (95% CI: 49.1, 54.2) in patients who received lanthanum carbonate (test group), 48.9 months (95% CI: 47.3, 50.5) in patients treated with other phosphate binders (concomitant therapy control group) and 40.3 months (95% CI: 38.9, 41.5) in patients before the availability of lanthanum carbonate (historical control group). Bone fracture rates were 5.9%, 6.7% and 6.4%, respectively. After more than 850 000 person-years of worldwide patient exposure, there is no evidence that lanthanum carbonate is associated with adverse safety outcomes in patients with end-stage renal disease.

Keywords: end-stage renal disease; hyperphosphatemia; lanthanum carbonate; long-term safety; pharmacokinetics; phosphate binder.


Figure 1
Figure 1
Comparison of the pharmacokinetics of lanthanum and aluminium. ESRD, end‐stage renal disease.
Figure 2
Figure 2
Kaplan–Meier analysis of time to all‐cause mortality based on United States Renal Data System data from 2014 (full analysis set). Horizontal reference line shows median survival time. CI, confidence interval.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles


    1. Block GA, Hulbert‐Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998; 31: 607–17. - PubMed
    1. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006; 70: 351–7. - PubMed
    1. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J. Am. Soc. Nephrol. 2005; 16: 1788–93. - PubMed
    1. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179–87. - PubMed
    1. Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol. Dial. Transplant. 2015; 30: 107–14. - PubMed

MeSH terms

Associated data